H. Lundbeck A/S · Copenhagen Denmark ·(OMX Copenhagen: LUN)

The health of the nervous system is central to H. Lundbeck's business plan. H. Lundbeck develops medicine primarily for the treatment of diseases of the central nervous system. Sold throughout the world, Lundbeck's main products include Cipralex (licensed to Forest Laboratories in the US market under the brand Lexapro) for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer's disease, and Azilect for the treatment of Parkinson's disease. Lundbeck spends about 20% of its revenue on research and development. The company has additional licensing and collaborative agreements with other drug makers including Teva Pharmaceuticals, Takeda, Merz, and Solvay.  To read the full description, subscribe now.